老虎證券

BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept

Reuters
02/23
BRIEF-Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept

Feb 23 (Reuters) - Bristol-Myers Squibb Co BMY.N:

  • BRISTOL MYERS SQUIBB ANNOUNCES POSITIVE TOP-LINE RESULTS FROM REGISTRATIONAL PHASE 2 STUDY OF LUSPATERCEPT IN ADULTS WITH ALPHA (Α)-THALASSEMIA

  • BRISTOL-MYERS SQUIBB CO - COHORTS MET PRIMARY AND SECONDARY ENDPOINTS

  • BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT INCREASE IN HEMOGLOBIN LEVELS

  • BRISTOL-MYERS SQUIBB CO - REBLOZYL SHOWED SIGNIFICANT DECREASE IN RBC TRANSFUSION BURDEN

  • BRISTOL-MYERS SQUIBB CO - SAFETY FINDINGS CONSISTENT WITH KNOWN PROFILE OF REBLOZYL IN THALASSEMIA

Source text: ID:nBwbFqRnta

Further company coverage: BMY.N

((Reuters.Briefs@thomsonreuters.com;))

應版權方要求，你需要登入查看該內容

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10